Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

NCT05652920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Ori-C101

Sponsor

OriCell Therapeutics Co., Ltd.